Abstract
We confirmed that IL-6 plays an oncogenic role in OSCC progression by activating JAK2/STAT3/Sox4/NLRP3 pathway, which might be the therapeutic targets for OSCC remedy.
Introduction
Oral squamous cell carcinoma (OSCC) accounts for approximately 95% of oral cancers, yet its five-year survival rate has remained stagnant between 50% and 60%. While chronic inflammation is a known hallmark of cancer, the precise molecular mechanisms connecting inflammatory signals to tumor growth in the oral cavity have been unclear. This study identifies Interleukin-6 (IL-6) as a key driver that hijacks cellular machinery to accelerate OSCC progression through the activation of the NLRP3 inflammasome.
Clinical Significance of IL-6 and Sox4
Researchers analyzed protein and mRNA levels in tissues from 108 OSCC patients, comparing them to healthy tissue and Oral Lichen Planus (OLP). The study found that both IL-6 and the transcription factor Sox4 are significantly overexpressed in OSCC tissues.
High expression levels of these markers correlate strongly with larger tumor size, advanced TNM stage, and significantly poorer overall survival. Furthermore, a strong positive correlation ($r = 0.8226, p < 0.0001$) was established between IL-6 and Sox4 expression, suggesting they function within the same regulatory axis.
Mechanistic Pathway: The Sox4 Bridge
Using OSCC cell lines (SCC-15 and SCC-25), the authors demonstrated that IL-6 promotes cell proliferation and colony formation in a dose-dependent manner. Mechanistically, IL-6 activates the JAK2/STAT3 signaling pathway, which directly upregulates Sox4. Sox4 then acts as a critical mediator to "turn on" the NLRP3 inflammasome, leading to the production of pro-inflammatory cytokines IL-1β and IL-18 that further fuel tumor growth.
The study confirmed via Chromatin Immunoprecipitation (ChIP) and luciferase assays that STAT3 physically binds to the Sox4 promoter, proving a direct regulatory link. In vivo mouse models validated these findings, showing that anti-IL-6 antibodies or Sox4 silencing dramatically slowed tumor growth and reduced inflammatory markers.
Conclusion
This research maps the IL-6/JAK2/STAT3/Sox4/NLRP3 axis as a major driver of OSCC progression. By identifying Sox4 as the bridge between classic oncogenic signaling and inflammasome activation, the study highlights new therapeutic targets. Future work may explore whether direct inhibition of the NLRP3 inflammasome offers a more precise treatment route with fewer side effects than broad JAK/STAT inhibition.
Summary updated